Bangladesh and Pakistan medical devices markets: size, growth and outlook 2026–2032

Two large, price-sensitive, import-dependent markets supplied largely from India and China. Published estimates normalised to 2025 range from USD 700 m to USD 822 m; the Consulting Wallah central estimate is USD 1.6 bn, growing at about 12% a year to USD 3.4 bn by 2032. Scope differences between publishers explain most of the spread — the comparison table below states each one.

Growth is driven by large populations (Pakistan >240 mn; Bangladesh ~170 mn) with rising chronic disease and low device penetration; bangladesh market CAGR ~13% (BIDA); Pakistan 12-15% (ITA) on private hospital expansion; bangladesh healthcare service industry growing 10.3% p.a.; fastest segment IVD.

Context that matters for buyers and suppliers: Bangladesh relies on imports for nearly 90% of medical device needs; imports USD 500-600 mn annually. Only 5-7% of >4,000 devices used in Bangladesh are locally made, mostly consumables (USD 55-60 mn). JMI Syringes supplies 100% of AD syringes for Bangladesh national immunisation and ~140 mn syringes/year. Pakistan imports >90% of medical devices; market USD 500-700 mn (2025).

The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is USD 700 m–USD 822 m; differences are mostly scope.

Included: capital equipment, implants, single-use consumables and IVD instruments and reagents. Excluded: pharmaceuticals, hospital IT, commodity PPE where reported separately. Publishers differ on whether IVD and consumables are included.

Shares as reported by the named sources; ranking is more reliable than the exact percentage.

• Bangladesh relies on imports for nearly 90% of medical device needs; imports USD 500-600 mn annually (The Business Standard)
• Only 5-7% of >4,000 devices used in Bangladesh are locally made, mostly consumables (USD 55-60 mn) (BIDA)
• JMI Syringes supplies 100% of AD syringes for Bangladesh national immunisation and ~140 mn syringes/year (The Business Standard)
• Pakistan imports >90% of medical devices; market USD 500-700 mn (2025) (S-GE; US ITA)
• DRAP regulates devices under Medical Devices Rules 2017 (DRAP Act 2012); registration valid 5 years; Class A enlistment in weeks, Class B/C/D 6-12 months (MedDeviceGuide)
• Classes B and C make up 61.4% of Pakistan DRAP device records (MedDeviceGuide)
• Abbott (792), Medtronic (495) and Roche (406) hold the most DRAP device records (MedDeviceGuide)
• Pakistan government healthcare expenditure ~USD 3.2 bn in FY2024 (US ITA)

Where the GCC and India sit

• Bangladesh medical device imports: USD 500-600 mn per year; ~90% import dependence (2026) — The Business Standard (JMI Group)
• Bangladesh import share of devices: 85%; import growth 10.2% (2014-2020) (2020) — BIDA
• Pakistan import share of devices: >90% (2026) — S-GE; MedDeviceGuide
• Pakistan government healthcare expenditure: USD ~3.2 bn (FY2024) — US ITA
• Pakistan DRAP register: 12,666 unique device records; ~500 company groups (2025) — MedDeviceGuide

Consulting Wallah works this market from both sides: hospital groups in the UAE, Saudi Arabia, India and Bangladesh as buyers, and manufacturers in India, China, Singapore, Malaysia and the US as suppliers through the Network. Our observation is that registration status, in-country stock and structured quotations decide access in the GCC, while price and distributor reach decide it in India. CW observation

Opportunities we see: local manufacturing of consumables/disposables (Bangladesh local output USD 55-60 mn; JMI meets ~60% of syringe demand); bangladesh pharma precedent (98% domestic supply) suggests policy-led localisation potential to USD 3 bn by 2030; pakistan Sialkot surgical-instrument export base and rising medical exports to China (>USD 11.4 mn).

Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.

• Manufacturers and exporters: registration first, local partner second, tender readiness third — see what GCC buyers need.
• Hospital leaders: total cost of ownership (service, consumables, software) outweighs purchase price; tender the bundle.
• Investors: local assembly and distribution platforms backed by procurement preference.

1. BIDA, Medical Equipment sector profile — bida.gov.bd
2. The Business Standard, Why Bangladesh must treat medical devices as an industry — tbsnews.net
3. US International Trade Administration, Pakistan Country Commercial Guide - Healthcare and Medical Equipment — trade.gov
4. MedDeviceGuide, Pakistan DRAP Registered Medical Devices Teardown & 2025 Ramp — meddeviceguide.com
5. Switzerland Global Enterprise, Pakistan Digital Health & MedTech Industry fact sheet 2026 — s-ge.com
6. Pure Global, DGDA Bangladesh Medical Device Registration — pureglobal.com
7. BIDA (Bangladesh Investment Development Authority) (2022) — USD 442 mn (2020) to USD ~820 mn (2025), CAGR 13%; scope: country / Bangladesh medical equipment market — source
8. World Bank (cited in The Business Standard op-ed, JMI Group) (2026-01) — USD 822 mn (2025) to USD 3 bn (long-term potential, policy-conditional) (2030), CAGR —; scope: country / Bangladesh medical devices; imports USD 500-600 mn p.a. — source
9. US International Trade Administration (Country Commercial Guide) (2026-03) — USD ~700 mn (2025) to — (2030), CAGR 12-15% (next five years); scope: country / Pakistan medical devices market — source
10. Consulting Wallah Network — anonymised observations from procurement and business-setup work with hospital groups and suppliers in the UAE, India and Bangladesh (2024–26), used for the GCC/India outlook and the “what it means” section.
11. Method. Each published figure is normalised to a 2025 base using its own CAGR; the Consulting Wallah central estimate is the median of the normalised figures (or the stated scope where noted) projected at the median CAGR to 2032. Country figures are quoted as published; where we add a CW estimate it is labelled.